What We're Reading: Page
Industry reads hand-picked by our editors
Mar 13, 2023
-
Reuters
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
-
Stat News
Biogen executive Samantha Budd Haeberlein leaves company
-
Associated Press
Prostate cancer treatment can wait for most men, study finds
-
Spectrum
Biotech downturn hurts companies targeting autism-linked conditions
Mar 10, 2023
-
The Information
Silicon Valley Bank CEO Tells VC Clients to ‘Stay Calm’
-
The Financial Times
Cost of gene treatments for once incurable diseases too high, scientists warn
-
Fortune
Read the letter Lux Capital sent to its investors, warning of ‘crushing consolidation in the venture industry’
-
MIT Technology Review
More than 200 people have been treated with experimental CRISPR therapies
Mar 09, 2023
-
Reuters
Bayer plans to spend $1 bln on US pharma R&D in 2023-US pharma head
-
Bloomberg
Ozempic and Wegovy Pose a Threat to WeightWatchers and Noom
-
Evaluate Vantage
The ink dries on the blank cheque craze
-
The New York Times
Keanu Reeves’s Latest Role? Fungus-Killing Bacterial Compound.
Mar 08, 2023
-
The New York Times
Could the Next Blockbuster Drug Be Lab-Rat Free?
-
The Wall Street Journal
Seagen’s Cancer Therapy Is Making It a Takeover Target
-
MIT Technology Review
Sam Altman invested $180 million into a company trying to delay death
Mar 07, 2023
Mar 06, 2023
-
The Wall Street Journal
What Is a CEO’s Pay Actually Worth?
-
The Boston Globe
Foundation stirs controversy by charging cancer patients $83,000 for unproven but promising experimental drug
-
Kaiser Health News
Despite Pharma Claims, Illicit Drug Shipments to US Aren’t Full of Opioids. It’s Generic Viagra.
Mar 03, 2023
-
NPR
FDA has new power to hold drugmakers accountable
-
Kaiser Health News
Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.
-
Reuters
U.S. regulators rejected Elon Musk’s bid to test brain chips in humans
-
MIT Technology Review
A technique called Cell Painting could speed drug discovery
Previous
